Been a holder for a while now, paying much closer attention to OSL's announcements and their trial results since BSI declined the CE last year. Will continue to hold but can't say I'm optimistic. I'd be wary about getting too carried away by statements like "closed out" and "rolling out". Not been impressed with their efforts with the regulators over these years and not convinced the trial data they take into market (if they get CE) will set the world alight or cut it with reimbursement bodies or many oncology specialists.
1. Disregard the company's spin around their panko data, what has actually changed between the rejection last March and now? It was a moderate safety trial in 2019, and is still a moderate safety trial in 2020. 2. No randomised control trial, no FDA. Simple. 3. Seem to be quite a lot of competing technologies for the type of patient studied in Panco- see paper by Ruarus, 'Cancer' 2018, google it. RFA, IRE (nanoknife), SABR, HIFU, Microwave ablation etc. Don't ever see these mentioned in company slides or analysts' reports. IRE for example has reasonable data in locally advanced panc cancer and the device is CE marked, but NICE (UK) won't fund it for this cancer (their guidance is also available on-line). SBRT making lot of advances. And OSL is planning an initial roll out of their device in England?
OSL Price at posting:
19.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)